{
  "meta": {
    "title": "Respiratory_Infections",
    "url": "https://brainandscalpel.vercel.app/respiratory-infections-df43462d.html",
    "scrapedAt": "2025-11-29T18:34:47.897Z"
  },
  "questions": [
    {
      "id": 1556,
      "choices": [
        {
          "id": 6219,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">20-40%</span></span></p>"
        },
        {
          "id": 6220,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0.4-2%</span></span></p>"
        },
        {
          "id": 6221,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2-10%</span></span></p>"
        },
        {
          "id": 6222,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">14-25%</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an obstetrics and gynecology rotation, a medical resident is learning about the complications associated with viral infections during pregnancy. A topic of particular interest is the risk of congenital varicella syndrome (CVS) in the fetus when a pregnant woman contracts the Varicella Zoster virus, especially during the first 20 weeks of gestation. The resident is asked about the likelihood of developing CVS in children born to mothers who become infected with Varicella Zoster virus during this critical period. What is the percentage risk of congenital varicella syndrome in these cases?</span></span></p>",
      "unique_key": "Q8070388",
      "question_audio": null,
      "question_video": null,
      "map_id": 34153,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 0.4-2%</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infection</strong> during <strong>pregnancy </strong>presents a <strong>risk</strong> for the <strong>foetus</strong> leading to <strong>congenital varicella syndrome</strong>. It occurs in <strong>0.4-2.0 percent</strong> of <strong>children born to mothers</strong> who become <strong>infected with VZV</strong> during the <strong>first 20 weeks of gestation.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella</strong>: Most <strong>threatening</strong> if transmitted in <strong>Ist trimester</strong> of <strong>pregnancy.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Common Gestational Periods for Vertical Transmission of Diseases -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella: First trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Rubella: First trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Parvovirus: Second Trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Syphilis: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Toxoplasmosis: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Hepatitis B: Third trimester</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital CMV: Third trimester</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital HIV: During delivery</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Congenital Hepatitis C: During delivery</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Herpes: During delivery</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>0.4 - 2% of children</strong> who <strong>acquire</strong> this condition <strong>born to mothers</strong> who become <strong>infected</strong> with <strong>Varicella Zoster virus</strong> during <strong>first 20 weeks of gestation.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 158)</strong></span></span></p>",
      "correct_choice_id": 6220,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1559,
      "choices": [
        {
          "id": 6231,
          "text": "<p><span style=\"font-size:12pt;\">1 to 2 days before rash and 4 to 5 days thereafter</span></p>"
        },
        {
          "id": 6232,
          "text": "<p><span style=\"font-size:12pt;\">4 to 5 days before rash and 1 to 2 days thereafter</span></p>"
        },
        {
          "id": 6233,
          "text": "<p><span style=\"font-size:12pt;\">3 to 4 days before rash and 4 to 5 days thereafter</span></p>"
        },
        {
          "id": 6234,
          "text": "<p><span style=\"font-size:12pt;\">1 day before rash and 2 days thereafter</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A medical resident treating a patient with chickenpox is discussing the case with a senior colleague. They talk about the infectious period of chickenpox, which is important for implementing appropriate isolation measures and preventing the spread of the infection. The resident is asked to identify the typical period during which a patient with chickenpox is infectious to others. When is the period of infectivity in a case of chickenpox?</span></p><p>&nbsp;</p>",
      "unique_key": "Q5435931",
      "question_audio": null,
      "question_video": null,
      "map_id": 34154,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. 1 to 2 days before rash and 4 to 5 days thereafter</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">&nbsp;<strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The <strong>period of communicability</strong> of patients with <strong>varicella </strong>is estimated to range from <strong>1 to 2 days</strong> <strong>before</strong> the appearance of <strong>rash</strong>, and <strong>4 to 5 days</strong> thereafter. The <strong>virus</strong> tends to <strong>die</strong> out <strong>before</strong> the <strong>pustular stage</strong>. The <strong>patient ceases</strong> to be <strong>infectious</strong> once the <strong>lesions</strong> have <strong>crusted.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Some important Pointers -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Chicken pox rash -&nbsp;<strong>Dew drop</strong> on <strong>rose petal</strong> appearance;&nbsp;<strong>Centripetal distribution</strong>;&nbsp;<strong>Pleomorphic rash</strong></span></li><li><span style=\"font-size:12pt;\"><strong>False</strong> about chickenpox is - <strong>Crusts</strong> contain <strong>live virus</strong></span></li><li><span style=\"font-size:12pt;\">Chickenpox<strong> Synonym</strong>: <strong>‘Varicella’</strong></span></li><li><span style=\"font-size:12pt;\">Causative agent: <strong>Varicella zoster virus</strong> [Human (alpha) <strong>Herpes Virus–3</strong>]</span></li><li><span style=\"font-size:12pt;\">Incubation period: <strong>14–16 days</strong></span></li><li><span style=\"font-size:12pt;\">Source of infection: Case (<strong>person-to-person contact</strong>)</span></li><li><span style=\"font-size:12pt;\"><strong>Mode</strong> of <strong>transmission</strong>: <strong>Air droplets</strong> (respiratory)</span></li><li><span style=\"font-size:12pt;\"><strong>Secondary Attack rate</strong>: <strong>90%MC</strong> late complication of <strong>chickenpox</strong>: <strong>Shingles</strong> (caused by <strong>reactivation</strong> of the <strong>virus decades</strong> after the <strong>initial episode of chickenpox</strong>)</span></li><li><span style=\"font-size:12pt;\">Most<strong> rapid and sensitive</strong> means of diagnosis: Examination of <strong>vesicle fluid</strong> under <strong>electron microscope</strong> (shows round particles)</span></li><li><span style=\"font-size:12pt;\">&nbsp;Congenital Varicella: <strong>Most threatening</strong> if transmitted in <strong>1<sup>st</sup></strong> <strong>trimester</strong> of <strong>pregnancy</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Live attenuated Chickenpox Monovalent Vaccine Strain</strong> -&nbsp;<strong>OKA</strong> strain</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>period of infectivity</strong> in a case of <strong>Chickenpox</strong> -&nbsp;<strong>1 to 2 days before</strong> <strong>rash</strong> and <strong>4 to 5 days thereafter.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 159)</strong></span></p>",
      "correct_choice_id": 6231,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1561,
      "choices": [
        {
          "id": 6239,
          "text": "<p><span style=\"font-size:12pt;\">Small pox</span></p>"
        },
        {
          "id": 6240,
          "text": "<p><span style=\"font-size:12pt;\">Measles</span></p>"
        },
        {
          "id": 6241,
          "text": "<p><span style=\"font-size:12pt;\">Dengue</span></p>"
        },
        {
          "id": 6242,
          "text": "<p><span style=\"font-size:12pt;\">Chickenpox</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A pediatric resident is evaluating a child at a Community Health Center (CHC) who presents with fever and a distinctive rash. Upon examination, the resident notes the simultaneous presence of papules, vesicles, and crusts all in the same area of the skin. This combination of lesions at different stages of development in the same area is characteristic of a specific viral infection. What is the most probable diagnosis for this child?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/18/image_4PQz4JP.png\" width=\"300\" height=\"170\"></span></p>",
      "unique_key": "Q3911264",
      "question_audio": null,
      "question_video": null,
      "map_id": 34155,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. Chickenpox</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A <strong>characteristic feature</strong> of the <strong>rash in chickenpox</strong> is its <strong>pleomorphism</strong>, that is, <strong>all stages</strong> of the <strong>rash (papules, vesicles and crusts)</strong> may be seen <strong>simultaneously at one time</strong>, in the <strong>same area</strong>. This is <strong>due</strong> to the <strong>rash</strong> appearing in <strong>successive crops </strong>for<strong> 4 to 5 days</strong> in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option</strong>&nbsp;<strong>A. Small pox:</strong>&nbsp;<strong>smallpox lesions</strong> appear in the <strong>same stage of development</strong> at the <strong>same time</strong> all over the body (<strong>non pleomorphic</strong>), <strong>unlike chickenpox</strong> where <strong>different stages</strong> are <strong>seen </strong>in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://my.clevelandclinic.org/-/scassets/images/org/health/articles/10855-smallpox\" alt=\"Smallpox: Causes, Symptoms, Treatment &amp; Prevention\" width=\"350\" height=\"202\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. Measles:</strong> &nbsp;<strong>Maculopapular rash</strong> that typically <strong>begins</strong> on the <strong>face and spreads downward</strong>. It does <strong>not </strong>present with <strong>lesions at different stages</strong> (papules, vesicles, crusts) in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image-20231128145356-1.jpeg\" width=\"350\" height=\"210\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Dengue:</strong> <strong>Dengue fever</strong> can present with a <strong>rash,</strong> but it is usually a <strong>diffuse erythematous rash</strong>, <strong>not</strong> one with <strong>papules, vesicles, and crusts</strong> in the <strong>same area.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\"><img src=\"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcRj7uaO9jM9z0k4dHy9_lFnLS9eMRr-Nksglw&amp;usqp=CAU\" alt=\"Exanthematic dengue fever mimicking rubella - ScienceDirect\" width=\"350\" height=\"204\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Chickenpox rash</strong> -&nbsp;<strong>Dew drop</strong> on <strong>rose</strong> <strong>petal appearance</strong>;&nbsp;<strong>Centripetal distribution;&nbsp;Pleomorphic rash.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Difference between Chicken Pox and Small Pox rash</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:16px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture11_HrNvuDK.jpg\" alt=\"\" width=\"1000\" height=\"963\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 159)</strong></span></p>",
      "correct_choice_id": 6242,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1565,
      "choices": [
        {
          "id": 6255,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">March</span></span></p>"
        },
        {
          "id": 6256,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">August</span></span></p>"
        },
        {
          "id": 6257,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">October&nbsp;</span></span></p>"
        },
        {
          "id": 6258,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">November&nbsp;</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a clinical discussion on the epidemiology of common viral infections, a medical resident asks about the seasonality of varicella-zoster virus (VZV) infections. Understanding the seasonal trends of infectious diseases is crucial for planning public health interventions and anticipating healthcare needs. Based on epidemiological patterns, in which of the following months is a varicella-zoster virus infection (chickenpox) more likely to occur?</span></span></p>",
      "unique_key": "Q8246186",
      "question_audio": null,
      "question_video": null,
      "map_id": 34156,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. March </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infection</strong> with <strong>varicella</strong> occurs <strong>year-round</strong>, although the incidence is found to <strong>peak in March, April and May</strong> in <strong>temperate climates.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>CHICKENPOX:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Also known as &lsquo;<strong>Varicella</strong>&rsquo;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Varicella zoster virus</strong> [Human (alpha) <strong>Herpes Virus &ndash; 3</strong>]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary attack rate: <strong>90%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>14&ndash;16 days</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rash:&nbsp;<strong>Dew drop</strong> on <strong>rose petal appearance</strong>;&nbsp;<strong>Centripetal distribution;&nbsp;Pleomorphic rash</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC late complication</strong> of <strong>Chickenpox</strong>: <strong>Shingles </strong>(caused by <strong>reactivation of</strong> the <strong>virus decades</strong> <strong>after </strong>the <strong>initial episode</strong> of <strong>chickenpox</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Aspirin </strong>must <strong>not</strong> be given to children with chickenpox: <strong>Risk of Reye&rsquo;s</strong> <strong>Syndrome</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Strain</strong> of <strong>Live attenuated Chickenpox Vaccine</strong>: <strong>OKA strain</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Congenital Varicella</strong>: <strong>Most threatening</strong> if transmitted in <strong>1<sup>st</sup> trimester</strong> of <strong>pregnancy</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Varicella-zoster virus</strong> infections (<strong>chickenpox</strong>) are more likely to occur in <strong>March,</strong> <strong>late winter and early spring</strong>, which is important for <strong>healthcare planning</strong> and <strong>public health interventions</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>:&nbsp;Clinical Maternal-Fetal Medicine by Winn, 1/e p263&nbsp;</strong></span></span></p>",
      "correct_choice_id": 6255,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1568,
      "choices": [
        {
          "id": 6267,
          "text": "<p><span style=\"font-size:12pt;\">0.15 ml per kg body weight</span></p>"
        },
        {
          "id": 6268,
          "text": "<p><span style=\"font-size:12pt;\">0.25 ml per kg body weight</span></p>"
        },
        {
          "id": 6269,
          "text": "<p><span style=\"font-size:12pt;\">0.35 ml per kg body weight</span></p>"
        },
        {
          "id": 6270,
          "text": "<p><span style=\"font-size:12pt;\">0.45 ml per kg body weight</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">During a clinical discussion on the management of measles, particularly in high-risk patients or those with contraindications to the measles vaccine, the topic of passive immunization arises. A medical resident is asked about the appropriate dosing of human immunoglobulin for providing passive immunity against measles. Understanding the correct dosage is crucial for effective post-exposure prophylaxis in susceptible individuals. What is the recommended dose of human immunoglobulin for passive immunization against measles?</span></p>",
      "unique_key": "Q1411244",
      "question_audio": null,
      "question_video": null,
      "map_id": 34157,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. 0.25 ml per kg body weight</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Measles</strong> may be <strong>prevented</strong> by administration of <strong>immunoglobulin (human)</strong> early in the <strong>incubation period</strong>. The <strong>dose</strong> recommended by <strong>WHO</strong> is <strong>0.25 ml</strong> per kg of <strong>body weight</strong> should be given <strong>within 4 days</strong> of <strong>exposure.</strong>&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">The person<strong> passively immunized</strong> should be given <strong>live vaccine, 8-12 weeks</strong> later.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Dose</strong> of <strong>human immunoglobulin</strong> for providing <strong>passive immunity</strong> <strong>against</strong> <strong>measles</strong> -&nbsp;<strong>0.25 ml</strong> per <strong>kg of body weight.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 165)</strong></span></p>",
      "correct_choice_id": 6268,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1570,
      "choices": [
        {
          "id": 6275,
          "text": "<p><span style=\"font-size:12pt;\">5 years</span></p>"
        },
        {
          "id": 6276,
          "text": "<p><span style=\"font-size:12pt;\">Lifelong</span></p>"
        },
        {
          "id": 6277,
          "text": "<p><span style=\"font-size:12pt;\">10 years</span></p>"
        },
        {
          "id": 6278,
          "text": "<p><span style=\"font-size:12pt;\">No immunity</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">During a pediatric infectious disease rotation, a medical student learns about the natural immunity conferred by viral infections. One topic of interest is the immunity that follows an infection with the measles virus. Understanding the duration of immunity after natural infection is important for patient counseling and future vaccination planning. After a patient recovers from an attack of measles, how long does the immunity typically last?</span></p>",
      "unique_key": "Q3867676",
      "question_audio": null,
      "question_video": null,
      "map_id": 34158,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. lifelong</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>No age</strong> is <strong>immune</strong> if there was <strong>no previous immunity</strong>. <strong>One</strong> attack of <strong>measles</strong> generally confers <strong>life-long immunity.</strong> <strong>Second attacks</strong> are <strong>rare</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Other diseases</strong> provide <strong>lifelong immunity</strong> with a <strong>single attack</strong> - <strong>Mumps, Rubella, Yellow fever.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">In <strong>measles disease</strong>, <strong>both</strong> <strong>natural infection and vaccination</strong> confer <strong>lifelong immunity/protection</strong> from infection of <strong>measles.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 162)</strong></span></p>",
      "correct_choice_id": 6276,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1571,
      "choices": [
        {
          "id": 6279,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 days</span></span></p>"
        },
        {
          "id": 6280,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 days</span></span></p>"
        },
        {
          "id": 6281,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">18 days</span></span></p>"
        },
        {
          "id": 6282,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">28 days</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is preparing for a public health campaign focused on maternal and child health, which includes educating about vaccine-preventable diseases such as rubella. During a team meeting, the topic of rubella&#39;s clinical course and its implications for public health is discussed. The resident is asked to explain the incubation period of rubella, also known as German measles, to help the team develop appropriate educational materials and strategies. What is the average incubation period of rubella?</span></span></p>",
      "unique_key": "Q7800867",
      "question_audio": null,
      "question_video": null,
      "map_id": 34159,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 18 days</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella</strong> has <strong>got</strong> an <strong>average incubation period</strong> of <strong>18 days (14-21 days).</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella (German Measles)</strong> - Some Important Pointers -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>RNA virus</strong> of <strong>Togavirus family</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Source of infection: <strong>Cases or subclinical cases</strong> &ndash; &lsquo;<strong>No known carrier state&rsquo;</strong> for <strong>postnatally</strong> <strong>acquired rubella</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mode of transmission: <strong>Air droplets</strong> (respiratory)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Period of communicability: <strong>One week prior to onset of symptoms</strong> to <strong>one</strong> <strong>week after rash appears.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunity for Rubella: &ndash; <strong>Single attack confers life long immunity</strong> (Second attacks rare)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>40%</strong> of reproductive age group <strong>females are susceptible</strong> in India</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infants</strong> <strong>protected</strong> till <strong>4-6 months of age</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>widely used test</strong> for diagnosis: <strong>Heme-agglutination Inhibition test</strong> (HAI) </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rubella Vaccine -&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Type of vaccine</strong>: <strong>Live attenuated, &lsquo;strain RA 27/3&rsquo;</strong>&nbsp;[Vaccine virus non-communicable]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dose and route: <strong>0.5 ml, subcutaneous</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella vaccine</strong> is <strong>contraindicated </strong>in <strong>pregnancy</strong> and <strong>not </strong>given to infants&nbsp;&ndash; If <strong>female vaccinated</strong> for <strong>rubella</strong>: Advice <strong>against pregnancy</strong> for <strong>next 3 months</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Priority groups for rubella vaccination in India:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1st PRIORITY: 15&ndash;49 years reproductive age</strong> group <strong>females</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>2nd priority</strong>: All children <strong>1&ndash;14 years age</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>3rd priority</strong>: <strong>Routine universal immunization</strong> of <strong>all children aged 1</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Average<strong> incubation period</strong> for <strong>German measles (Rubella)</strong> - <strong>18 days (14-21</strong> <strong>days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period of some important diseases -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture12.jpg\" style=\"height:1009px; width:1000px\" /></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 166)</strong></span></span></p>",
      "correct_choice_id": 6281,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1572,
      "choices": [
        {
          "id": 6283,
          "text": "<p><span style=\"font-size:12pt;\">RA 27/3 strain</span></p>"
        },
        {
          "id": 6284,
          "text": "<p><span style=\"font-size:12pt;\">Jeryll lynn strain</span></p>"
        },
        {
          "id": 6285,
          "text": "<p><span style=\"font-size:12pt;\">Edmonston Zagreb strain&nbsp;</span></p>"
        },
        {
          "id": 6286,
          "text": "<p><span style=\"font-size:12pt;\">17 D strain</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During a public health campaign aimed at increasing vaccination rates, a 30-year-old pediatrician is discussing the rubella vaccine with his interns. He emphasizes the importance of understanding the components of vaccines, including the specific viral strains used, to effectively communicate with the community and address any concerns. He poses a question to his interns about the strain of the virus used in the current rubella vaccines. Which strain of the virus is used in the current rubella vaccines?</span></p>",
      "unique_key": "Q1199618",
      "question_audio": null,
      "question_video": null,
      "map_id": 34160,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. RA 27/3 strain</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The currently used <strong>rubella vaccines</strong> are based on the <strong>live attenuated RA 27/3 strain.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Some <strong>important</strong> Pointers related to <strong>Rubella Vaccine</strong> -&nbsp;</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Type</strong> of vaccine: <strong>Live attenuated</strong>, ‘<strong>strain RA 27/3’</strong> [Vaccine virus non-communicable]&nbsp;.</span></li><li><span style=\"font-size:12pt;\"><strong>Rubella vaccine</strong> is <strong>contraindicated</strong> in <strong>pregnancy</strong> and <strong>not </strong>given <strong>to infants</strong>&nbsp; If <strong>female vaccinated</strong> for <strong>rubella</strong>: Advice <strong>against pregnancy</strong> for <strong>next 3</strong> <strong>months.</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Priority</strong> groups for <strong>rubella vaccination</strong> in <strong>India:</strong></span><ul><li><span style=\"font-size:12pt;\"><strong>1st PRIORITY</strong>: <strong>15–49</strong> years <strong>reproductive age</strong> group females</span></li><li><span style=\"font-size:12pt;\"><strong>2nd priority</strong>: All <strong>children 1–14 years age</strong></span></li><li><span style=\"font-size:12pt;\"><strong>3rd priority</strong>: Routine <strong>universal immunization</strong> of all children <strong>aged 1</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;B. Jeryll lynn strain</strong> - Mumps vaccine&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;C. Edmonston Zagreb strain</strong> - Measles vaccine</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option&nbsp;D. 17 D strain</strong> - Yellow Fever Vaccine&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Rubella</strong> vaccine <strong>strain -</strong> <strong>RA 27/3</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Vaccines and different strains :</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:16px;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture13.jpg\" alt=\"\" width=\"1000\" height=\"697\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ref: Park 26<sup>th</sup> edition (page 167)</strong></span></p>",
      "correct_choice_id": 6283,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1573,
      "choices": [
        {
          "id": 6287,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pancreatitis</span></span></p>"
        },
        {
          "id": 6288,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Orchitis</span></span></p>"
        },
        {
          "id": 6289,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Sensorineural deafness</span></span></p>"
        },
        {
          "id": 6290,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cholecystitis</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 5-year-old child presents to the outpatient department (OPD) with a 2-day history of bilateral tender neck swelling, accompanied by low-grade fever, myalgia, and headache. Based on the presentation, a likely diagnosis is a viral infection typically causing parotitis. The medical resident is considering potential complications of the disease and discusses this with a colleague. Which of the following is NOT a recognized complication of this disease, the condition likely affecting this child?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><img alt=\"Mumps | Photos | CDC\" src=\"https://www.cdc.gov/mumps/images/people_mumps.jpg?_=95438\" /></span></p>",
      "unique_key": "Q2623204",
      "question_audio": null,
      "question_video": null,
      "map_id": 34161,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Cholecystitis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>complications</strong> for <strong>mumps</strong> include <strong>orchitis, ovaritis, pancreatitis, meningoencephalitis, thyroiditis, neuritis, hepatitis</strong> and <strong>myocarditis</strong>.&nbsp; <strong>Rarer</strong> complications include <strong>nerve deafness, polyarthritis, hydrocephalus, encephalitis, cerebellar ataxia, facial palsy</strong> and <strong>transverse myelitis</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps</strong> is one of the main <strong>infectious causes of sensorineural deafness</strong>, which affects approximately<strong> 5 per 100,000 mumps cases</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Some Important Pointers related to MUMPS </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Myxovirus parotiditis</strong> (<strong>RNA paramyxovirus)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation Period:<strong> 14-21</strong> days</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Source of Infection: Clinical &amp; subclinical cases</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mode of transmission</strong>: <strong>Air droplets (respiratory)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Period of Communicability:</strong> <strong>4-6 days</strong> <strong>before </strong>to <strong>7 days after</strong> <strong>onset</strong> of <strong>symptoms</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps</strong> show <strong>lifelong immunity</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Secondary attack</strong> rate of Mumps: <strong>86%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Clinical features:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Salivary (esp. Parotid) glands</strong> involvement</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC complication: Aseptic meningitis</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC </strong>complication in <strong>adolescents: Orchitis, Oophoritis</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mumps is <strong>prevented</strong> by: <strong>Active</strong> immunization by <strong>Mumps vaccine</strong> &ndash; Type: <strong>Live attenuated vaccine</strong> (Strain: <strong>Jeryll Lynn strain</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>complications of Mumps</strong> include <strong>Orchitis, Pancreatitis, Sensorineural deafness</strong> but <strong>not</strong> <strong>Cholecystitis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 168)</strong></span></span></p>",
      "correct_choice_id": 6290,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1574,
      "choices": [
        {
          "id": 6291,
          "text": "<p><span style=\"font-size:12pt;\">26%</span></p>"
        },
        {
          "id": 6292,
          "text": "<p><span style=\"font-size:12pt;\">66%</span></p>"
        },
        {
          "id": 6293,
          "text": "<p><span style=\"font-size:12pt;\">86%</span></p>"
        },
        {
          "id": 6294,
          "text": "<p><span style=\"font-size:12pt;\">100%</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During an epidemiology lecture at a medical school, the professor discusses the transmission dynamics of various viral infections. Mumps, a contagious viral infection, is highlighted for its notable secondary attack rate, particularly in settings where close contact occurs, such as schools and family households. A medical student is asked about the secondary attack rate of mumps to understand its transmissibility. What is the secondary attack rate of mumps?</span></p>",
      "unique_key": "Q5007617",
      "question_audio": null,
      "question_video": null,
      "map_id": 34162,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 86%</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Secondary attack rate for mumps is estimated to be about 86 percent.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Secondary Attack Rate (SAR)</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Is no. of exposed persons developing the disease within the range of incubation period (IP), following exposure to the primary case</span></li><li><span style=\"font-size:12pt;\">Denominator includes only those susceptible in close contact</span></li><li><span style=\"font-size:12pt;\">Primary case is always excluded both from numerator and denominator for SAR calculation</span></li></ul><p>&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:20px;\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture14.jpg\" alt=\"\" width=\"1000\" height=\"690\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Secondary Attack Rate of some diseases&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Secondary attack rate of Mumps - 86% (&gt;85%)</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Infectivity is also termed as Secondary attack rate</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 168)</strong></span></p>",
      "correct_choice_id": 6293,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1575,
      "choices": [
        {
          "id": 6295,
          "text": "<p><span style=\"font-size:12pt;\">45 mg OD of Oseltamivir</span></p>"
        },
        {
          "id": 6296,
          "text": "<p><span style=\"font-size:12pt;\">75 mg OD of Oseltamivir</span></p>"
        },
        {
          "id": 6297,
          "text": "<p><span style=\"font-size:12pt;\">45 mg OD of Zanamivir</span></p>"
        },
        {
          "id": 6298,
          "text": "<p><span style=\"font-size:12pt;\">70 mg OD of Zanamivir</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">During an infectious disease rotation, a medical resident is tasked with developing a protocol for managing potential outbreaks of Influenza H1N1 in a hospital setting. As part of the protocol, the resident must consider options for chemoprophylaxis, especially for high-risk patients and healthcare workers who may be exposed to the virus. The resident discusses with the supervising physician about the appropriate medication for chemoprophylaxis against Influenza H1N1.&nbsp; Which medication is recommended for chemoprophylaxis against Influenza H1N1?</span></p>",
      "unique_key": "Q2579267",
      "question_audio": null,
      "question_video": null,
      "map_id": 34163,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B. 75 mg of Oseltamivir</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Oseltamivir (Tamiflu)</strong> is the drug of choice for<strong> chemoprophylaxis to health care personnel and close contacts</strong> of suspected, <strong>probable or confirmed</strong> case of <strong>pandemic influenza A (H1N1)</strong> 2009. It should be given till <strong>10 days after last exposure</strong>.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>For adults</strong> above <strong>40 kg</strong> the dose is <strong>75 mg OD.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>H1N1 (Type A)</strong> – Cause of <strong>Swine flu</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Antiviral</strong> therapy for <strong>H1N1</strong>:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Severe/progressive</strong> clinical illness: <strong>Oseltamivir</strong> (if <strong>not available</strong> or <strong>resistant</strong>, use <strong>Zanamivir</strong>)</span></li><li><span style=\"font-size:12pt;\"><strong>High risk</strong> of <strong>severe/complicated</strong> illness<strong>: Oseltamivir OR Zanamivir</strong></span></li><li><span style=\"font-size:12pt;\"><strong>Not</strong> high risk OR <strong>Uncomplicated</strong> confirmed/suspected illness: <strong>No</strong> need of <strong>treatment</strong></span></li><li><span style=\"font-size:12pt;\">Dosage:</span><ul><li><span style=\"font-size:12pt;\"><strong>Oseltamivir</strong> - <strong>75 mg BD</strong> × <strong>5 days</strong> (DOC)</span></li><li><span style=\"font-size:12pt;\"><strong>Zanamivir</strong> - <strong>2 inhalations</strong> (<strong>2 × 5</strong> mg) <strong>BD</strong> × <strong>5 days</strong></span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Chemoprophylaxis</strong>&nbsp;against&nbsp;<strong>H1N1 - Oseltamivir 75 mg OD</strong> till <strong>10 days</strong> after <strong>last exposure.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Reference: Park 26<sup>th</sup> edition (page 175)</strong></span></p>",
      "correct_choice_id": 6296,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1580,
      "choices": [
        {
          "id": 6315,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carriers are more common sources of infection than cases</span></span></p>"
        },
        {
          "id": 6316,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period is 2-6 days</span></span></p>"
        },
        {
          "id": 6317,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">25 Lf of diphtheria toxoid are present per ml in DPT vaccine</span></span></p>"
        },
        {
          "id": 6318,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diphtheria is an endemic disease in India</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a community health center is reviewing the epidemiology and clinical aspects of diphtheria as part of a public health initiative. The resident is presented with a series of statements about diphtheria and is asked to identify which one is NOT true. This exercise is important for ensuring accurate understanding and effective communication about the disease to the public. Which of the following statements about diphtheria is NOT true?</span></span></p>",
      "unique_key": "Q2669764",
      "question_audio": null,
      "question_video": null,
      "map_id": 34164,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 25 Lf of diphtheria toxoid are present per ml in DPT vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DPT VACCINE:-</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Composition -&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-093455.png\" style=\"height:734px; width:1000px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT vaccine contains <strong>Thiomersal </strong>(<strong>Preservative</strong>)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT contains <strong>Aluminum hydroxide/ aluminium phosphate</strong> (<strong>Adjuvant</strong>).&nbsp;It <strong>increases immunogenicity</strong> of vaccine</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Absolute Contraindications</strong> to <strong>DPT vaccine</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Severe hypersensitivity reaction</strong> to <strong>previous dose </strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Progressive neurological disease</strong> (e.g. ACTIVE Epilepsy) [Cerebral palsy &amp; seizures controlled on anti-epileptics do not preclude the use of DPT; DPT should be given under these circumstances]</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cold Chain Temperature</strong> of <strong>DPT</strong>: <strong>+2&deg; to +8&deg;C</strong>&nbsp; (If DPT vaccine gets frozen accidentally, then have to&nbsp;discard the vaccine)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult</strong> type of <strong>Diphtheria &ndash; tetanus vaccine</strong> (dT): contains up to <strong>2 Lf</strong> of <strong>diphtheria toxoid</strong> per dose; given <strong>2 doses</strong> <strong>4-6 weeks apart</strong>, followed by a <strong>booster</strong> after <strong>6&ndash;12 months</strong>; is useful for <strong>immunizing</strong> children over <strong>12 yrs of age</strong> &amp; <strong>adults</strong> (Incl. <strong>Pregnant women</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;A</strong>. <strong>Carriers are more common sources of infection than cases</strong>: &nbsp;<strong>TRUE</strong>.&nbsp;<strong>95%</strong> of total disease <strong>transmission</strong> is due to <strong>carriers</strong>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nasal carriers</strong> are <strong>more dangerous</strong> than <strong>throat carriers</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence of carriers</strong> in a community: <strong>0.5-1%</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Immunization <strong>does not</strong> prevent <strong>carrier state</strong></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Note -&nbsp;<strong>Source of infection</strong>: <strong>Case or carrier</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. Incubation period is 2-6 days</strong>: &nbsp;<strong>TRUE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mode</strong> of <strong>transmission</strong>: <strong>droplet infection</strong> (main mode), directly from <strong>cutaneous lesions and fomites</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Period of Infectivity</strong>: <strong>14-28 days</strong> from <strong>onset of disease</strong>; longer for carriers.</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>case/carrier</strong> may be considered <strong>non-communicable</strong> when at least <strong>2 cultures</strong> from <strong>nose and throat</strong>, <strong>24 hrs apart</strong>, are <strong>negative.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC</strong> Subtype: <strong>Faucial</strong> (<strong>Tonsillar + Pharyngeal</strong>)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Diphtheria is an endemic disease in India</strong>: &nbsp;<strong>TRUE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DPT</strong> vaccine - <strong>25 Lf</strong> of <strong>diphtheria toxoid</strong> are present per <strong>0.5 ml</strong> i.e. <strong>per dose.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DT&nbsp;</strong>Vaccine - Contains up to <strong>2 Lf</strong> of <strong>diphtheria toxoid</strong> per <strong>dose.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 27<sup>th</sup> edition (page 180)&nbsp;</strong></span></span></p>",
      "correct_choice_id": 6317,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1584,
      "choices": [
        {
          "id": 6331,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MR vaccine</span></span></p>"
        },
        {
          "id": 6332,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MMR vaccine</span></span></p>"
        },
        {
          "id": 6333,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MMRV vaccine</span></span></p>"
        },
        {
          "id": 6334,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Hexavalent vaccine</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a pediatric clinic is reviewing the National Immunization Schedule as part of a public health initiative to improve vaccination rates in the community. Recently, there have been updates to the schedule, particularly regarding the measles vaccine. The resident is discussing these changes with a senior pediatrician to ensure accurate information is provided to patients and their families. In the National Immunization Schedule, the measles vaccine has been replaced by which of the following vaccines?</span></span></p>",
      "unique_key": "Q6284347",
      "question_audio": null,
      "question_video": null,
      "map_id": 34165,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. MR vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>National Immunisation Schedule</strong>, <strong>Measles</strong> vaccine has been <strong>replaced</strong> by <strong>Measles Rubella (MR) vaccine.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;MMR</strong>: &nbsp;Is a type of <strong>live attenuated vaccine</strong>, recommended at the age of <strong>15&ndash;18 months.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NOTE - In <strong>Delhi&rsquo;s Immunization Schedule</strong>, there are <strong>2 additional vaccines</strong> &ndash; <strong>MMR</strong> (<strong>single</strong> dose at <strong>15 months</strong> of age) and&nbsp;<strong>Typhoid </strong>(<strong>single dose</strong> between <strong>2-5</strong> <strong>years</strong> of age)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. &nbsp;MMRV Combination Vaccine:&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Given </strong>at age group of <strong>9 months&ndash;12 years</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Minimum</strong> interval between <strong>2 doses</strong>: <strong>4 weeks</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Preferable schedule: <strong>2nd dose</strong> <strong>6 weeks-3 months later</strong> or at <strong>4-6 years age.</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>The maximum</strong> age for administration of <strong>MMRV</strong> is&nbsp;<strong>12 years</strong>. It should <strong>not </strong>be administered to <strong>anyone 13 years of age or older</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. &nbsp;Hexavalent Vaccine:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There is <strong>no hexavalent vaccine</strong> available in <strong>India</strong> that contains <strong>MMR </strong>in combination.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>National Immunisation Schedule</strong>, <strong>Measles vaccine</strong> has been <strong>replaced by</strong> <strong>Measles Rubella (MR) vaccine</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NEW <strong>National Immunization Schedule</strong> (NIS) <strong>2023-24</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-125017_KHN9A8u.png\" style=\"height:1129px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NOTE -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>JE vaccine</strong> only in <strong>Endemic districts</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>HiB Vaccine</strong> introduced as <strong>Pentavalent vaccine</strong> &ndash; <strong>DPT + HepB + HiB</strong> vaccine in <strong>16 states.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>fIPV</strong> is fractionated <strong>intradermal at 6 weeks</strong> &amp; <strong>14 weeks</strong> or <strong>IPV Intramuscular </strong>only at <strong>14 weeks</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rotaviral vaccine</strong> introduced in <strong>9 States</strong> &ndash; Andhra Pradesh, Haryana, Himachal Pradesh, Odisha, Madhya Pradesh, Assam, Rajasthan, Tamil Nadu and Tripura.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles-Rubella/ MR vaccine</strong> started from <strong>5 States/UTs</strong> - Karnataka, Tamil Nadu, Goa, Lakshadweep and Puducherry.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pneumococcal conjugate</strong> PCV vaccine introduced in all 12 districts of Himachal Pradesh, 6 districts of Uttar Pradesh and 17 districts of Bihar</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult JE Vaccine</strong> introduced in <strong>31 high burden districts</strong> from <strong>Assam</strong>, <strong>Uttar Pradesh and West Bengal</strong> for <strong>adult</strong>. <strong>JE vaccination</strong> in the age-group of <strong>15-65 years.&nbsp;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MoHFW-GOI</strong> (<strong>August 2018</strong>) - <strong>TT </strong>be <strong>replaced</strong> by <strong>Td</strong>; Replacement for <strong>TT booster </strong>doses given <strong>at 10 years, 16 years</strong> age and <strong>Pregnant women</strong> (incl<strong>. booster dose</strong>).</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 732)</strong></span></span></p>",
      "correct_choice_id": 6331,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1586,
      "choices": [
        {
          "id": 6339,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Catch up</span></span></p>"
        },
        {
          "id": 6340,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Follow up</span></span></p>"
        },
        {
          "id": 6341,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Outreach vaccination</span></span></p>"
        },
        {
          "id": 6342,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">High risk immunisation</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident working in a community health center is involved in planning a measles immunization program. As part of the program, various strategies are being considered to effectively increase measles immunity in the community. The resident is tasked with identifying key components of the immunization strategy, particularly activities that are unique and not regularly repeated. In the context of a measles immunization program, which of the following activities is considered a &lsquo;one-time activity&rsquo; aimed at rapidly increasing community immunity levels?</span></span></p>",
      "unique_key": "Q3248567",
      "question_audio": null,
      "question_video": null,
      "map_id": 34166,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Catch up</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles Catch-up campaigns</strong> -&nbsp;Catch up is a <strong>onetime event</strong>. During the <strong>measles</strong> <strong>catch up</strong> campaign all the children in <strong>target age group</strong> (<strong>9 months to 14</strong> years) will receive a <strong>supplementary dose of Measles vaccine</strong> regardless of <strong>previous vaccination history</strong> or <strong>history</strong> of <strong>measles disease</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>WHO Measles Elimination</strong> Strategy: &lsquo;<strong>Catch up, keep up, Follow up&rsquo;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Catch up</strong>: <strong>One time Nationwide</strong>, <strong>vaccination</strong> campaign targeting all children <strong>9 months to 14 years of age</strong>, irrespective of history of Measles disease or vaccination status</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Keep up</strong>: <strong>Routine services</strong> aimed at <strong>vaccinating</strong> more than <strong>95%</strong> of each <strong>successive birth cohort.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Follow up</strong>: <strong>Subsequent nationwide vaccination</strong> campaigns conducted every <strong>2&ndash;4 years</strong> targeting usually <strong>all children born</strong> <strong>after</strong> the <strong>catch-up campaign</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Accelerated Measles Mortality Reduction Strategy</strong> (WHO/UNICEF):<strong>&nbsp;Two doses</strong> of <strong>Measles containing vaccine</strong> (MCV) to <strong>all children</strong> through <strong>routine</strong> and <strong>supplementary immunization activities.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. Follow up: </strong>&nbsp;<strong>Subsequent nationwide vaccination campaigns</strong> conducted every<strong> 2&ndash;4 years</strong>&nbsp;(not one-time event) targeting usually all <strong>children born</strong> <strong>after</strong> the <strong>catch-up campaign</strong>. (Part of WHO Measles Elimination Strategy: &lsquo;Catch up, keep up, Follow up&rsquo;)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C.&nbsp;Outreach vaccination</strong>: &nbsp;While outreach vaccination is important for <strong>reaching underserved</strong> or <strong>hard-to-reach populations</strong>, it is generally an <strong>ongoing activity</strong> rather than a one-time event.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. High risk immunization: </strong>&nbsp;Immunization of high-risk groups is an important <strong>part</strong> of <strong>any immunization strategy</strong> but is typically an <strong>ongoing effort</strong> rather than a one-time activity.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles Catch-up campaigns </strong>-&nbsp; <strong>One time Nationwide</strong>, <strong>vaccination campaign</strong> targeting all children <strong>9 months to 14 years of age</strong>, <strong>irrespective</strong> of history of <strong>Measles disease or vaccination status.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 730)</strong></span></span></p>",
      "correct_choice_id": 6339,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1588,
      "choices": [
        {
          "id": 6347,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Penicillin</span></span></p>"
        },
        {
          "id": 6348,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Erythromycin</span></span></p>"
        },
        {
          "id": 6349,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Doxycycline</span></span></p>"
        },
        {
          "id": 6350,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an infectious disease rotation, a medical resident is consulted about a patient who is identified as a carrier of Corynebacterium diphtheriae, the bacterium responsible for diphtheria. While the patient is asymptomatic, the resident understands the importance of treating carriers to prevent the spread of the infection. The resident discusses with the supervising physician about the appropriate pharmacological intervention for carriers of diphtheria. What is the recommended drug for treating carriers of<strong> </strong>diphtheria?</span></span></p>",
      "unique_key": "Q8437868",
      "question_audio": null,
      "question_video": null,
      "map_id": 34167,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. Erythromycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>carriers of Diphtheria </strong>should be <strong>treated</strong> with <strong>10 days</strong> course of <strong>oral erythromycin</strong>, which is the <strong>most effective</strong> drug for the <strong>treatment of carriers</strong>.&nbsp;This <strong>antibiotic</strong> is <strong>effective</strong> in <strong>eliminating</strong> the <strong>bacterium</strong> from the <strong>nasopharynx</strong>, thereby <strong>reducing</strong> the <strong>risk of transmission.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;A. Penicillin: </strong>&nbsp;can be used as <strong>DOC</strong> for treating <strong>Diphtheria</strong> <strong>Cases</strong> not carriers.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C. Doxycycline: </strong>&nbsp;<strong>Drug of choice</strong> for <strong>chemoprophylaxis</strong> for <strong>Malaria</strong>, if needed for<strong> &lt;6 weeks</strong> (not for diphtheria)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Rifampicin: </strong>&nbsp;<strong>Drug of choice</strong> for <strong>chemoprophylaxis</strong> for <strong>Meningococcal</strong> <strong>meningitis</strong> (not for diphtheria)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of Choice</strong> in <strong>Diphtheria:-</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\">&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155339.png\" style=\"height:463px; width:1000px\" /></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drugs for Chemoprophylaxis:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-155111.png\" style=\"height:642px; width:1000px\" /></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 177)</strong></span></span></p>",
      "correct_choice_id": 6348,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1590,
      "choices": [
        {
          "id": 6355,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Human and animals are the reservoirs of infection</span></span></p>"
        },
        {
          "id": 6356,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There are no subclinical cases.</span></span></p>"
        },
        {
          "id": 6357,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The incubation period is fairly fixed at ten days.</span></span></p>"
        },
        {
          "id": 6358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Effective vaccine is available.</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health seminar focusing on vaccine-preventable diseases, a discussion arises about the global efforts to eliminate measles. A medical resident is reviewing various factors that support the potential elimination of measles in the near future. The resident considers the key elements that contribute to the successful control and eventual elimination of measles but also recognizes challenges that might impede these efforts. Which of the following points is NOT in favor of the elimination of measles in the near future?</span></span></p>",
      "unique_key": "Q7531549",
      "question_audio": null,
      "question_video": null,
      "map_id": 34168,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Human and animals are the reservoirs of infection</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Human beings</strong> are the <strong>only reservoir</strong> of infection. <strong>Man</strong> is <strong>Obligate Host</strong>. This is one of the reason for <strong>elimination of measles</strong> in the <strong>future.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;B. There are no subclinical cases: </strong>&nbsp;Correct.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;C. The incubation period is fairly fixed at ten days: </strong>&nbsp;Correct</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option&nbsp;D. Effective vaccine is available: </strong>&nbsp;Correct.&nbsp;Very effective vaccine is available.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Eradication </strong>of <strong>Measles</strong>: Requires a <strong>vaccination coverage &gt;96%.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemic </strong>of <strong>measles</strong> occur: If the proportion of <strong>susceptible children is &gt;40%.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">If <strong>Measles </strong>is <strong>introduced </strong>in a <strong>virgin community</strong>: it <strong>infects &gt;90%</strong> children.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The experience of <strong>eradicating polio</strong> and <strong>small pox</strong> using <strong>similar strategies</strong> of <strong>vaccination</strong> combined with <strong>surveillance and contamination</strong> already exist.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other reasons</strong> for the <strong>elimination of measles</strong> in the <strong>future:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source </strong>of Infection are&nbsp;<strong>only cases</strong>&nbsp;(carriers are not known to occur)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles </strong>has <strong>no second attacks</strong> (<strong>lifelong immunity</strong> seen)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Manifestations</strong> of disease are <strong>well known</strong> to the <strong>community</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Reasons</strong> for the <strong>elimination of measles</strong> in the <strong>future:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Human beings</strong> are the <strong>only reservoir</strong> of infection. <strong>Man</strong> is <strong>Obligate Host.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source of Infection</strong> are&nbsp;<strong>ONLY CASES</strong>&nbsp;(carriers are not known to occur).</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There are <strong>no subclinical cases.</strong></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Manifestations</strong> of disease are <strong>well known</strong> to the community.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Measles has <strong>no second attacks</strong> (lifelong immunity seen).</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>incubation period</strong> is <strong>fairly fixed at ten days</strong>.</span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Very effective</strong> vaccine is <strong>available.</strong>&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar- 4<sup>th</sup> edition (page 731)</strong></span></span></p>",
      "correct_choice_id": 6355,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1591,
      "choices": [
        {
          "id": 6359,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pertussis</span></span></p>"
        },
        {
          "id": 6360,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculosis</span></span></p>"
        },
        {
          "id": 6361,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Plague</span></span></p>"
        },
        {
          "id": 6362,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diphtheria</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While attending a lecture on respiratory illnesses in children, a medical student learns about various infectious diseases that present with prolonged coughing. The lecturer emphasizes the importance of recognizing specific clinical patterns in diagnosis. One disease, known for its characteristic and protracted cough, is highlighted for being notoriously referred to as the &quot;Hundred-day cough.&quot; The student is asked to identify this disease based on its distinctive clinical presentation. Which respiratory illness is commonly known as the &quot;Hundred-day cough&quot; due to its prolonged and characteristic coughing episodes?</span></span></p>",
      "unique_key": "Q3471435",
      "question_audio": null,
      "question_video": null,
      "map_id": 34169,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Pertussis</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">An <strong>acute infectious disease</strong>, usually of <strong>young children</strong>, caused by <strong>B. pertussis</strong>. It is clinically characterized by an <strong>insidious onset</strong> with <strong>mild fever</strong> and an <strong>irritating cough</strong>, gradually becoming <strong>paroxysmal</strong> with the characteristic &ldquo;<strong>whoop</strong>&rdquo; (loud crowing inspiration) often with <strong>cyanosis and vomiting</strong>. The <strong>spectrum of disease</strong> varies from <strong>severe illness to atypical and mild illness</strong> <strong>without whoop</strong>. The Chinese call it a &ldquo;<strong>Hundred Day Cough</strong>&rdquo;.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;Tuberculosis: Incorrect.</strong> Serious <strong>respiratory illness</strong> caused by <strong>Mycobacterium tuberculosis</strong>. TB symptoms include a <strong>persistent cough</strong>, but the disease is known for <strong>its systemic symptoms</strong> and potential for <strong>severe lung damage</strong> rather than the <strong>duration of coughing episodes</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Plague:</strong> <strong>Incorrect.</strong> Caused by <strong>Yersinia pestis</strong>, can have a respiratory form known as <strong>pneumonic plague</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Diphtheria: Incorrect</strong>. Bacterial infection caused by <strong>Corynebacterium diphtheriae</strong>. While it affects the respiratory system, it is <strong>not</strong> associated with the <strong>prolonged cough</strong>, as characteristic of <strong>pertussis</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers related to&nbsp;Pertussis/Whooping Cough -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Causative agent: <strong>Bordetella pertussis</strong> (<strong>5%</strong> cases by <strong>B. parapertussis</strong>)<br />\r\n&bull; Also known as &lsquo;<strong>Whooping Cough&rsquo;</strong> or &lsquo;<strong>100 Day Cough&rsquo;</strong> &ndash; <strong>Paroxysms</strong> of cough are followed by an <strong>inspiratory whoop</strong> (high pitch)<br />\r\n&bull; Incubation period<strong>: 7&ndash;14 days</strong><br />\r\n&bull; Source of Infection: <strong>Case</strong><br />\r\nThere is <strong>no subclinical or chronic carrier state.</strong><br />\r\n<strong>Neither</strong> <strong>vaccination nor infection</strong> <strong>confers long-term immunity.</strong><br />\r\n&bull;<strong> Secondary Attack rate: &gt; 90%</strong><br />\r\n&bull; Incidence and fatality: Females &gt; Males.<br />\r\n&bull; <strong>Leukocytosis</strong> does <strong>not</strong> correlates with the <strong>severity of cough.</strong><br />\r\n&bull; Chief complications: Bronchitis, <strong>bronchopneumonia,</strong> bronchiectasis, <strong>subconjunctival hemorrhages</strong>, epistaxis, <strong>hemoptysis</strong>, punctuate cerebral hemorrhages, <strong>convulsions and coma</strong>.<br />\r\n&bull; Laboratory diagnosis: Culturing of <strong>nasopharyngeal swabs</strong> on <strong>Bordet-Gengou medium,</strong> polymerase chain reaction (<strong>PCR</strong>), <strong>immunofluorescence (DFA),</strong> and <strong>serological methods</strong><br />\r\n&bull; Drug of choice:<strong> Erythromycin (40 mg/kg QID &times; 10 days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Hundred Day Cough</strong> is - <strong>Pertussis (Whooping Cough</strong>) - caused by<strong> Bordetella</strong> <strong>pertussis).</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
      "correct_choice_id": 6359,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1595,
      "choices": [
        {
          "id": 6375,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More in Males</span></span></p>"
        },
        {
          "id": 6376,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">More in Females</span></span></p>"
        },
        {
          "id": 6377,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Equal in Males and females</span></span></p>"
        },
        {
          "id": 6378,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Differs in Males and Females in different states</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in a pediatric clinic is reviewing epidemiological data on pertussis (whooping cough) as part of his research project. Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease. While vaccination has significantly reduced its incidence, there are concerns about increasing cases in certain populations. The resident is analyzing trends in the incidence and fatality of pertussis, particularly in vulnerable groups, to better understand the current challenges in managing and preventing this disease. Which statement accurately reflects the current trends in the incidence and fatality of pertussis?</span></span></p>",
      "unique_key": "Q6664301",
      "question_audio": null,
      "question_video": null,
      "map_id": 34170,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. More in females</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence and fatality</strong> of <strong>Pertussis</strong> are observed to be <strong>more</strong> among <strong>female </strong>than male children.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some <strong>Important</strong> Pointers related to&nbsp;<strong>Pertussis/Whooping Cough</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Causative agent: <strong>Bordetella pertussis</strong> (5% cases by B. parapertussis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Also known as &lsquo;<strong>Whooping Cough&rsquo; or &lsquo;100 Day Cough&rsquo;</strong> &ndash; <strong>Paroxysms </strong>of <strong>cough</strong> are followed by an <strong>inspiratory whoop (high pitch)</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incubation period: <strong>7&ndash;14 days</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Source of Infection</strong>: <strong>Case</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">There is <strong>no subclinical or chronic carrier state</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Neither vaccination nor infection </strong>confers<strong> long-term immunity.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Secondary</strong> Attack rate: &gt; <strong>90%</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Incidence and fatality: <strong>Females </strong>&gt; Males</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Leukocytosis </strong>does <strong>not</strong> correlates with the <strong>severity of cough</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chief complications: Bronchitis, <strong>bronchopneumonia</strong>, bronchiectasis, <strong>subconjunctival hemorrhages</strong>, epistaxis, <strong>hemoptysis,</strong> <strong>punctuate cerebral </strong>hemorrhages, convulsions and coma.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Laboratory diagnosis: <strong>Culturing</strong> of <strong>nasopharyngeal swabs</strong> on <strong>Bordet-Gengou</strong> <strong>medium</strong>, polymerase chain reaction (<strong>PCR)</strong>, immunofluorescence (<strong>DFA</strong>), and <strong>serological methods</strong>.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drug of choice: <strong>Erythromycin (40 mg/kg QID &times; 10 days)</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Incidence and fatality of Pertussis</strong> are observed to be <strong>more </strong>among <strong>female than</strong> <strong>male</strong> children.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
      "correct_choice_id": 6376,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1607,
      "choices": [
        {
          "id": 6423,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cotrimoxazole</span></span></p>"
        },
        {
          "id": 6424,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Doxycycline</span></span></p>"
        },
        {
          "id": 6425,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Erythromycin</span></span></p>"
        },
        {
          "id": 6426,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ciprofloxacin</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a primary care setting, a family medicine physician encounters a family where one child has been diagnosed with pertussis. Recognizing the contagious nature of the disease, the physician considers the appropriate treatment protocol not only for the affected child but also for the family members who have been in close contact. The physician reviews the latest treatment guidelines to ensure the recommended first-line therapy is provided to both the patient and the contacts to effectively control the spread of the disease.&nbsp; What is the recommended first-line therapy for treating individuals diagnosed with pertussis and their close contacts?</span></span></p>",
      "unique_key": "Q8964566",
      "question_audio": null,
      "question_video": null,
      "map_id": 34171,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Erythromycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Cases:</strong> Although <strong>several antibiotics</strong> are <strong>effective</strong> against <strong>B. pertussis,</strong> <strong>erythromycin</strong> is probably the <strong>drug of choice.</strong> A dose of <strong>30-50 mg/kg</strong> of body weight in <strong>4 divided doses</strong> for <strong>10 days</strong> has been recommended.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Contacts:</strong> Those <strong>known </strong>to have been in <strong>contact with whooping cough</strong> may be given <strong>prophylactic antibiotic</strong> (<strong>erythromycin or azithromycin</strong>) treatment for <strong>10 days</strong> to prevent the <strong>infecting bacteria</strong> to become <strong>established.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Cotrimoxazole: </strong>Incorrect. <strong>Not </strong>the <strong>first-line</strong> treatment for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. &nbsp;Doxycycline: </strong>Incorrect. Doxycycline can be <strong>used</strong> in <strong>certain cases,</strong> especially in <strong>older children and adults</strong>, but it is <strong>not</strong> typically the <strong>first-line</strong> treatment for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Ciprofloxacin</strong>: Incorrect. <strong>Not</strong> used as the <strong>first-line treatment</strong> for <strong>pertussis.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of choice</strong> for <strong>Pertussis Case</strong> and <strong>Contact</strong>: <strong>Erythromycin (40 mg/kg QID X 10 days)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref:</u></strong><strong> Park 26<sup>th</sup> edition (page 180)</strong></span></span></p>",
      "correct_choice_id": 6425,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1611,
      "choices": [
        {
          "id": 6439,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Whooping cough is more infectious during catarrhal stage</span></span></p>"
        },
        {
          "id": 6440,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage</span></span></p>"
        },
        {
          "id": 6441,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Asymptomatic chronic carriers of B. pertussis are common</span></span></p>"
        },
        {
          "id": 6442,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary attack rate is 90%</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident in a public health clinic is advising parents about pertussis (whooping cough) as part of an educational initiative. Bordetella pertussis, the bacterium responsible for pertussis, has a specific period during which it is infectious. The resident needs to be well-informed about this infective period to provide accurate advice on prevention and control measures, such as isolation and treatment. However, there are some misconceptions about the infective period of B. pertussis. Which of the following statements is NOT true regarding the infective period of Bordetella pertussis?</span></span></p>",
      "unique_key": "Q3735188",
      "question_audio": null,
      "question_video": null,
      "map_id": 34172,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Asymptomatic chronic carriers of B. pertussis are common</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Asymptomatic</strong> <strong>chronic carriers</strong> of <strong>B. pertussis</strong> are <strong>uncommon.</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>Pertussis</strong> -&nbsp;<strong>Subclinical cases</strong> do <strong>not</strong> <strong>exist</strong>.&nbsp; (Source of Infection: <strong>ONLY Cases</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Whooping cough is more infectious during the catarrhal stage:</strong> <strong>True</strong>. The <strong>catarrhal stage</strong>, which is the <strong>early</strong> phase of <strong>whooping cough</strong>, is characterized by<strong> symptoms</strong> similar to a <strong>common cold</strong>. During this stage, the <strong>disease</strong> is <strong>highly infectious.</strong> <strong>Catarrhal stage</strong> (<strong>1 week after exposure </strong>to <strong>3 weeks after</strong> <strong>onset of paroxysmal stage</strong>, although communicability <strong>diminishes</strong> <strong>rapidly after the catarrhal stage</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Infective period may extend from a week after exposure to about 3 weeks after the onset of paroxysmal stage:</strong> <strong>True</strong>.&nbsp;The <strong>infective period</strong> for <strong>whooping</strong> cough can <strong>last</strong> from the <strong>initial exposure </strong>through the <strong>paroxysmal stage</strong>, during which <strong>severe coughing</strong> fits occur.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Secondary attack rate is 90%: True</strong>. The secondary attack rate for <strong>whooping cough</strong> is <strong>very high</strong>, meaning that the disease is <strong>highly contagious</strong> within <strong>households or close-contact settings.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers related to PERTUSSIS -&nbsp;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Drug of choice</strong>:<strong> Erythromycin (40 mg/kg in 4 divided doses X 10 days)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Complications: Bronchitis, <strong>bronchopneumonia</strong>, bronchiectasis, convulsions, coma</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While <strong>whooping</strong> cough is <strong>highly contagious</strong> during the <strong>catarrhal stage</strong> and has a <strong>high secondary attack</strong> rate,&nbsp;the <strong>asymptomatic chronic carriers</strong> of <strong>B. pertussis</strong> are <strong>uncommon</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">SAR of some diseases are: </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture17.jpg\" style=\"height:833px; width:1000px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 179)</strong></span></span></p>",
      "correct_choice_id": 6441,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1613,
      "choices": [
        {
          "id": 6447,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DPT</span></span></p>"
        },
        {
          "id": 6448,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">BCG</span></span></p>"
        },
        {
          "id": 6449,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococcal vaccine</span></span></p>"
        },
        {
          "id": 6450,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Measles Rubella (MR)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An intern, as part of their pediatric clinic rotation, is focusing on the safety profiles of childhood vaccines. This review is crucial to enhance their understanding of vaccine safety and to better counsel parents effectively. In particular, the intern is examining the rare but serious side effects that can occur post-vaccination. The topic of discussion shifts to convulsions, a serious complication that can be associated with certain vaccines, albeit rarely. The intern is tasked with identifying the specific vaccine linked to this adverse effect. Which vaccine is known to have a rare association with convulsions as a serious post-immunization complication?</span></span></p>",
      "unique_key": "Q5466872",
      "question_audio": null,
      "question_video": null,
      "map_id": 34173,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. DPT</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Following <strong>DPT vaccine,</strong> the <strong>rare</strong> vaccine reactions are <strong>persistent</strong> (more than <strong>3 hours</strong>) inconsolable screaming, <strong>seizures</strong>, <strong>hypotonic hypo-responsive episodes</strong>, <strong>anaphylactic reaction</strong>, and very rarely <strong>encephalopathy.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. BCG (Bacillus Calmette&ndash;Gu&eacute;rin):</strong> <strong>Incorrect</strong>. The complications associated with BCG vaccine are <strong>Prolonged severe ulceration</strong> at <strong>site</strong> of <strong>vaccination</strong>, Suppurative <strong>lymphadenitis</strong>,&nbsp;<strong>Osteomyelitis</strong>,&nbsp;<strong>Disseminated BCG infection</strong> and&nbsp;<strong>Death</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Meningococcal vaccine:</strong> <strong>Incorrect</strong>.&nbsp;In rare cases, a meningococcal vaccine may cause a&nbsp;<strong>severe allergic reaction</strong> (Hypersensitivity).</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. MR (Measles and Rubella):</strong> <strong>Incorrect</strong>. Although <strong>febrile convulsions</strong> can occur following the<strong> MR vaccine</strong> due to <strong>fever</strong>, the association is <strong>less prominent</strong> compared to the <strong>DPT vaccine</strong>.&nbsp;<strong>Measles (&amp; MMR)</strong> vaccine can lead to <strong>Toxic Shock Syndrome.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some <strong>Specific side effects</strong> of important vaccines are:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <strong><em>Guillian Barre Syndrome: </em>Killed influenza vaccine</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&bull; <em>Vaccine associated paralysis: </em>OPV (Sabin)</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <em>Shock: </em>DPT, Pertussis vaccine</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; <em>Hypersensitivity: </em>Hep-B, Meningococcal vaccine, DPT, dT </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>rare</strong> vaccine reactions <strong>post DPT vaccination</strong> are <strong>persistent</strong> (more than <strong>3 hours</strong>) inconsolable <strong>screaming, seizures, hypotonic hypo-responsive episodes, anaphylactic reaction,</strong> and very rarely <strong>encephalopathy.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Rare vaccine reactions:</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154619.png\" style=\"height:850px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 180)</strong></span></span></p>",
      "correct_choice_id": 6447,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1620,
      "choices": [
        {
          "id": 6475,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">X</span></span></p>"
        },
        {
          "id": 6476,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Y</span></span></span></p>"
        },
        {
          "id": 6477,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Z</span></span></p>"
        },
        {
          "id": 6478,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">W135</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During an epidemiology lecture at a medical school, the topic of Neisseria meningitidis (the causative agent of meningococcal meningitis) is being discussed. The professor explains that various serotypes of N. meningitidis are responsible for the disease&#39;s epidemiology, including both endemic cases and outbreaks. A medical student, interested in infectious diseases, is asked to identify the serotype of N. meningitidis that is less commonly associated with causing both endemic disease and outbreaks. Which serotype of Neisseria meningitidis is typically NOT associated with causing both endemic disease and outbreaks?</span></span></p>",
      "unique_key": "Q4510582",
      "question_audio": null,
      "question_video": null,
      "map_id": 34174,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Z</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>12 serotypes</strong> have been<strong> identified</strong>, viz. <strong>Groups</strong> <strong>A, B, C, 29E, H, I, K, L, W135, X, Y, Z</strong> based on the structure of the <strong>polysaccharide capsule.</strong>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The majority of invasive<strong> meningococcal infections</strong> are caused by organisms of <strong>serogroups A, B, C, X, W135</strong> and <strong>Y</strong>. <strong>Meningococci</strong> of these <strong>serogroups</strong> have the potential to cause <strong>both endemic disease and outbreaks</strong>. </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>lethal</strong> form is <strong>B</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Epidemics - A, C &gt; B &gt; W-135, Y</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In <strong>African meningitis belt</strong>, <strong>subgroup A</strong> has been the most <strong>important</strong> cause of <strong>disease</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Neisseria meningitides</strong> Serotype <strong>not</strong> associated with <strong>endemics and outbreaks - Serotype Z.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>MC serotype</strong> of <strong>Meningococcus</strong> causing <strong>epidemics</strong> <strong>worldwide</strong> is <strong>A</strong> and the most <strong>lethal form</strong> is <strong>B.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 181)</strong></span></span></p>",
      "correct_choice_id": 6477,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1628,
      "choices": [
        {
          "id": 6507,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">15 year</span></span></p>"
        },
        {
          "id": 6508,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2 years</span></span></p>"
        },
        {
          "id": 6509,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 years</span></span></p>"
        },
        {
          "id": 6510,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 years</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a paediatric immunization clinic, a nurse practitioner is educating a group of new parents about the vaccination schedule for their infants. One of the vaccines discussed is the quadrivalent meningococcal vaccine, which offers protection against four strains of Neisseria meningitidis. A parent inquires about the appropriate age to start this vaccination for their child. The nurse practitioner knows that the vaccine&#39;s efficacy and safety are age-dependent and prepares to explain the age guidelines.&nbsp;At what minimum age is the quadrivalent meningococcal vaccine typically not recommended in children?</span></span></p>",
      "unique_key": "Q6202962",
      "question_audio": null,
      "question_video": null,
      "map_id": 34175,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 2 years</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Quadrivalent vaccines</strong> are administered as a <strong>single dose</strong> to individuals aged <strong>&gt; 2 years</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Important pointers regarding <strong>Meningococcal Vaccine</strong> -</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Type of Vaccine: <strong>killed vaccine, cellular fraction</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose: 0.5 ml</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Route: <strong>Subcutaneous</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Site: Antero-lateral thigh (Middle one-third)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Booster every <strong>3 years</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Available for <strong>group A, C, W135 and Y meningococci</strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Vaccine is <strong>not </strong>available for <strong>Group B meningococcus</strong>: Group B polysaccharide is <strong>non-immunogenic.</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contraindications:</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Pregnancy</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Infants and children &lt; 2 years</strong> of age (due to development of <strong>immunologic tolerance</strong>)</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Meningococcal Vaccine</strong> - <strong>Contraindications</strong> - <strong>Pregnant women, Infants</strong> and children <strong>&lt;2 years</strong> of age.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 182)</strong></span></span></p>",
      "correct_choice_id": 6508,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1631,
      "choices": [
        {
          "id": 6519,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mass vaccination</span></span></p>"
        },
        {
          "id": 6520,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Health education</span></span></p>"
        },
        {
          "id": 6521,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isolation of cases</span></span></p>"
        },
        {
          "id": 6522,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mass chemoprophylaxis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health department meeting, a medical officer is discussing strategies for controlling an outbreak of meningococcal meningitis in a community. Various measures are considered, including vaccination and antibiotic prophylaxis. However, certain interventions are not recommended in the control of meningococcal meningitis epidemics. The medical officer is reviewing these strategies to ensure that the response is evidence-based and effective. In the control of an epidemic of meningococcal meningitis, which of the following interventions is NOT recommended?</span></span></p>",
      "unique_key": "Q1856961",
      "question_audio": null,
      "question_video": null,
      "map_id": 34176,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Isolation of Cases</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Isolation</strong> of cases is <strong>not</strong> useful in <strong>epidemics of meningococcal meningitis</strong> as <strong>carriers outnumber cases</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Mass vaccination:</strong> &nbsp;This is a recommended intervention in the control of a <strong>meningococcal meningitis epidemic</strong>. Vaccination is <strong>effective</strong> in <strong>preventing </strong>the <strong>spread </strong>of the <strong>disease</strong>, especially in <strong>areas </strong>with <strong>high incidence rates</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Health education: &nbsp;HE</strong> is an important <strong>component</strong> of <strong>epidemic control</strong>. Educating the public about the<strong> symptoms</strong> of <strong>meningococcal meningitis</strong> and the importance of seeking timely <strong>medical care</strong> can help in <strong>early detection</strong> and <strong>treatment of cases</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Mass chemoprophylaxis: </strong>&nbsp;Mass chemoprophylaxis, using <strong>antibiotics</strong> like <strong>rifampicin, ciprofloxacin, or ceftriaxone</strong>, can be recommended in certain situations during a <strong>meningococcal meningitis epidemic</strong>. It is particularly used for <strong>close contacts of infected individuals</strong> to <strong>prevent</strong> the <strong>spread</strong> of the <strong>disease</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some Important Pointers</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>DOC</strong> for <strong>Chemoprophylaxis</strong> of <strong>Meningococcal Meningitis</strong> - <strong>Rifampicin (600 mg BD &times; 2 days).</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Meningococcal disease</strong> is <strong>endemic</strong> in India.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment with <strong>Penicillin doesn&rsquo;t eradicate</strong> the <strong>carrier state</strong> in <strong>meningococcal meningitis.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningococcal Meningitis Prevention &amp; Control</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of cases: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antibiotics</strong> <strong>started &lt; 48 hours</strong> of illness save <strong>95% lives.</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drug of choice: <strong>Penicillin</strong> (Ceftriaxone if allergic to Penicillin)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Epidemics</strong>: <strong>Single dose</strong> Long-acting <strong>Chloramphenicol or Ceftriaxone</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of carriers: Rifampici</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of contacts:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Start treatment &lt; 24 hours</strong> of identification of <strong>index case</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Drugs used: Rifampicin, Ciprofloxacin, Ceftriaxone, Azithromycin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the control of a <strong>meningococcal meningitis epidemic</strong>, <strong>isolation</strong> of individual cases is <strong>not</strong> a typically recommended intervention. <strong>Mass vaccination</strong> and <strong>chemoprophylaxis</strong>, along with <strong>health education</strong>, are key strategies in <strong>controlling and preventing</strong> the <strong>spread of the disease.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar (4<sup>th</sup> edition) (page 757)</strong></span></span></p>",
      "correct_choice_id": 6521,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1639,
      "choices": [
        {
          "id": 6551,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Outpatient treatment</span></span></p>"
        },
        {
          "id": 6552,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Give injection/ oral drops</span></span></p>"
        },
        {
          "id": 6553,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Home management</span></span></p>"
        },
        {
          "id": 6554,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Urgent referral</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pediatric resident is evaluating a 6-month-old infant in a community health center. The infant presents with high fever, rapid breathing, and a convulsion. The resident refers to the IMNCI (Integrated Management of Neonatal and Childhood Illnesses) chart for guidance on management. According to the IMNCI chart, what does the pink color indicate regarding the necessary action for this patient?</span></span></p>",
      "unique_key": "Q5618463",
      "question_audio": null,
      "question_video": null,
      "map_id": 34177,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Urgent referral</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Under <strong>IMNCI,</strong> <strong>pink color</strong> in <strong>chart</strong> refers to <strong>urgent referral.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>IMNCI</strong> classifications are <strong>colour coded</strong> :</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>pin</strong>k&rdquo; suggests <strong>hospital referral or admission</strong>, </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>yellow</strong>&rdquo; indicates <strong>initiation of treatment</strong>, and </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&ldquo;<strong>green</strong>&rdquo; calls for <strong>home treatment</strong>.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Outpatient treatment: </strong>Yellow color</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.&nbsp;Give injection/ oral drops - </strong>yellow color<strong>&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Home management - </strong>green color</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Integrated Management of Neonatal and Childness illness (IMNCI)</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IMNCI </strong>is a strategy for <strong>reducing morbidity and mortality</strong> associated with <strong>major</strong> causes of <strong>childhood illness.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Curative component</strong> includes management of:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Diarrhoea</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. Measles</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. Pneumonia</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. Malaria</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5. Severe malnutrition and nutritional counseling</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Case management process</strong>: Is presented in a series of charts (Mnemonic: <strong>A Case Is Treated &amp; Care Given</strong>).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Assess the young infant or child</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Classify the illness</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Identify the treatment</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treat the infant or child</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Counsel the mother</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Give follow-up care</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Example - <strong>IMNCI</strong> guidelines for <strong>Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine- Rajvir Bhalwar (4<sup>th</sup> edition) (page 428)</strong></span></span></p>",
      "correct_choice_id": 6554,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1641,
      "choices": [
        {
          "id": 6559,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Very severe disease</span></span></p>"
        },
        {
          "id": 6560,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Severe pneumonia</span></span></p>"
        },
        {
          "id": 6561,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pneumonia</span></span></p>"
        },
        {
          "id": 6562,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">No pneumonia- cough or cold</span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In a pediatric clinic, a medical resident is evaluating a series of infants under 2 months old as part of an initiative to enhance early disease detection and management. The resident is utilizing the Integrated Management of Neonatal and Childhood Illnesses (IMNCI) guidelines to classify the severity of illnesses in these young patients. While discussing the cases with a senior pediatrician, the resident is asked to identify which classification is not typically used in the IMNCI guidelines for infants less than 2 months old.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following is NOT a classification under the IMNCI for this age group?</span></span></p>",
      "unique_key": "Q2945086",
      "question_audio": null,
      "question_video": null,
      "map_id": 34178,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the <strong>IMNCI classification</strong> for <strong>infants less than 2 months old</strong>, the specific category of <strong>&#39;Pneumonia&#39; is not used</strong>. <strong>Instead,</strong> respiratory conditions are classified as <strong>&#39;Severe pneumonia&#39; or &#39;Very severe disease.&#39;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong><strong>&nbsp;</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Very severe disease</strong>: <strong>Incorrect</strong>. This includes <strong>critical signs</strong> like&nbsp;<strong>Stopped feeding well</strong>, <strong>convulsions</strong>, abnormally sleepy or<strong> difficult</strong> to <strong>wake</strong>, <strong>stridor</strong> in <strong>calm</strong> <strong>child, wheezing</strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Severe pneumonia: Incorrect</strong>. &#39;Severe pneumonia&#39; characterized by symptoms like <strong>chest indrawing</strong> and <strong>fast breathing</strong> (<strong>60 per minute or more</strong>)</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. No pneumonia-cough or cold:</strong> <strong>Incorrect</strong>. This term is <strong>used</strong> when an <strong>infant </strong>presents with a <strong>cough or cold</strong> but <strong>does not</strong> show <strong>signs of pneumonia</strong> or <strong>very severe disease</strong> i.e.&nbsp;<strong>No </strong>severe <strong>chest indrawing</strong> and <strong>no fast breathing.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>IMNCI</strong> guidelines for <strong>pneumonia</strong> (NEW, 2017 Guideline)</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">If <strong>0-2 months</strong> old <strong>Young Infant</strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&bull; Count the <strong>breaths </strong>(recount, if <strong>&gt;60/min</strong>)<br />\r\n&bull; Look for <strong>severe</strong> <strong>chest indrawing</strong>.&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\">&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/28/image_bI6qll7.png\" style=\"height:142px; width:540px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2 month - 5 year child</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/08/screenshot-2024-08-08-154152.png\" style=\"height:1246px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the <strong>IMNCI </strong>classification for <strong>infants less than 2 months</strong> old, the specific category of &#39;<strong>Pneumonia</strong>&#39; is <strong>not used.</strong> Instead, <strong>respiratory conditions</strong> are <strong>classified</strong> as <strong>&#39;Severe pneumonia&#39; or &#39;Very severe disease.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 187)</strong></span></span></p>",
      "correct_choice_id": 6561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 1670,
      "choices": [
        {
          "id": 6675,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pneumonia</span></span></p>"
        },
        {
          "id": 6676,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diarrhoea</span></span></p>"
        },
        {
          "id": 6677,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dengue</span></span></p>"
        },
        {
          "id": 6678,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Meningitis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a public health policy meeting, a medical resident reviewed various initiatives and campaigns launched to combat significant health issues in children. One of the initiatives discussed is the SAANS campaign, launched in November 2019. The resident is tasked with identifying the specific disease targeted by the SAANS initiative, as understanding these campaigns is crucial for effective public health planning and patient education. The SAANS initiative, launched in November 2019, was aimed at combating which disease?</span></span></p>",
      "unique_key": "Q8744650",
      "question_audio": null,
      "question_video": null,
      "map_id": 34152,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Pneumonia</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong> Campaign <strong>2019</strong> (Launched on <strong>16th November 2019</strong>)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong>: <strong>Social Awareness and Action plan to Neutralise pneumonia Successfully&nbsp;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Target: To <strong>reduce Childhood mortality</strong> due to <strong>Pneumonia</strong> to <strong>less</strong> than <strong>3 per</strong> <strong>1000 Live Birth by 2025</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Objectives:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Awareness in community</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Awareness of care</strong> gives to <strong>identify early</strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dispels myths</strong> and <strong>notions and trigger</strong> behaviour change</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Target beneficiaries:</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Primary beneficiaries: All care givers, Mothers, Fathers</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Secondary beneficiaries: Key Opinion Leaders (Gram Panchayat Leaders, Local Administration, Religious Leaders, Village Health Sanitation and Nutrition Committee Members, ICDS, Private practitioners)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/12/picture22.jpg\" style=\"height:164px; width:300px\" />&nbsp;<img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/19/image_4j10Igd.png\" style=\"height:174px; width:404px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SAANS</strong> Campaign <strong>2019</strong> - for <strong>Childhood Pneumonia.&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u>:https://nhm.gov.in/index1.php?lang=1&amp;level=4&amp;sublinkid=1336&amp;lid=716</strong></span></span></p>",
      "correct_choice_id": 6675,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}